Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Stock Information for Acurx Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Acurx Pharmaceuticals Inc.

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Update: Agenus Aug 27 Stakeholder Webcast-Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025
From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.